About adagrasib
KRAS G12C inhibitor
Used for
- Treats certain adults with advanced non-small cell lung cancer caused by KRAS G12C mutation, after prior treatment.
Usual adult dose
600 mg by mouth twice daily until disease worsens or side effects become unacceptable.
Common side effects
- Diarrhea, nausea, vomiting, and abdominal pain
- Fatigue and decreased appetite
- Liver enzyme increases
- QT interval prolongation, which can affect heart rhythm
Important warnings
- Can cause serious liver injury; liver tests are monitored during treatment.
- Can prolong the QT interval and cause dangerous heart rhythms.
- Severe diarrhea or vomiting can cause dehydration and kidney problems.
- Avoid grapefruit and grapefruit juice; they may raise drug levels.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Acid-reducing medicines may lower absorption; timing or choice may need adjustment.
- Strong CYP3A inhibitors can increase drug levels and side effects.
- Strong CYP3A inducers can reduce drug levels and effectiveness.
- Can affect levels of some medicines, including sensitive CYP3A substrates.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.